Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash from Operations (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Cash from Operations data on record, last reported at 29718000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 18.91% year-over-year to 29718000.0; the TTM value through Dec 2025 reached 138886000.0, down 5.62%, while the annual FY2025 figure was 138886000.0, 5.62% down from the prior year.
  • Cash from Operations reached 29718000.0 in Q4 2025 per TNGX's latest filing, up from 30952000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 7518000.0 in Q2 2021 and bottomed at 41697000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 27848800.0, with a median of 29691500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: plummeted 23493650.0% in 2021, then grew 22.4% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 16902000.0 in 2021, then tumbled by 67.23% to 28266000.0 in 2022, then grew by 2.83% to 27467000.0 in 2023, then plummeted by 33.42% to 36647000.0 in 2024, then rose by 18.91% to 29718000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 29718000.0 in Q4 2025, 30952000.0 in Q3 2025, and 36519000.0 in Q2 2025.